Cerus (CERS) Liabilities and Shareholders Equity (2010 - 2026)
Cerus (CERS) posted Liabilities and Shareholders Equity of $205.2 million for Q2 2026, down 7.95% sequentially from $222.9 million in Q1 2026, and down 3.7% YoY from $213.1 million in Q2 2025.
Cerus (CERS) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Cerus has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $205.2 million in Q2 2026.
- Quarterly Liabilities and Shareholders Equity fell 3.7% year-over-year to $205.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $865.1 million (up 6.77% YoY) and the FY2025 annual result came in at $221.9 million, up 10.42% from the prior year.
- Liabilities and Shareholders Equity eased to $205.2 million in Q2 2026 per CERS's latest filing, from $222.9 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $222.9 million in Q1 2026 and troughed at $185.5 million in Q2 2024.
- A 5-year average of $207.4 million and a median of $208.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity dropped 9.65% in 2024, then grew 14.87% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $218.1 million in 2022, then slipped by 9.33% to $197.7 million in 2023, then grew by 1.6% to $200.9 million in 2024, then advanced by 10.42% to $221.9 million in 2025, then retreated by 7.51% to $205.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $205.2 million, $222.9 million, and $221.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Cerus | 560.58 Mn | 504.32 Mn | 29.53 Mn | 205.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 205.19 Mn |
| Mar 31, 2026 | 222.91 Mn |
| Dec 31, 2025 | 221.86 Mn |
| Sep 30, 2025 | 215.19 Mn |
| Jun 30, 2025 | 213.07 Mn |
| Mar 31, 2025 | 206.78 Mn |
| Dec 31, 2024 | 200.92 Mn |
| Sep 30, 2024 | 189.54 Mn |
| Jun 30, 2024 | 185.50 Mn |
| Mar 31, 2024 | 189.14 Mn |
| Dec 31, 2023 | 197.75 Mn |
| Sep 30, 2023 | 205.84 Mn |
| Jun 30, 2023 | 198.86 Mn |
| Mar 31, 2023 | 209.34 Mn |
| Dec 31, 2022 | 218.09 Mn |
| Sep 30, 2022 | 215.40 Mn |
| Jun 30, 2022 | 216.46 Mn |
| Mar 31, 2022 | 221.91 Mn |
| Dec 31, 2021 | 237.50 Mn |
| Sep 30, 2021 | 218.95 Mn |